#IMNN

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 IMUNON , Inc. (Nasdaq: IMNN) Dear Valued Shareholders,

2 months ago

#IMNN IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

www.stocktitan.net/news/IMNN/imunon-2025-a-...

0 0 0 0

3 months ago

#IMNN: R&D Day Highlights Potential for IMNN-001… buff.ly/vhcV1eD

0 0 0 0

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update R&D Day showcased remarkable Investigator optimism, continued strengthening supportive data, and significant progress with Phase 3 OVATION 3 Study in pursuit of first frontline immunotherapy for advanced ovarian cancer Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov.

4 months ago

#IMNN IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IMNN/imunon-reports...

0 0 0 0

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer IMUNON (Nasdaq: IMNN) hosted a public webcast on Nov 10, 2025 presenting translational and clinical data for its DNA-mediated immunotherapy IMNN-001.Speakers included cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 MRD trials, clinicians, statistical experts and IMUNON executives. The event highlighted clinical findings that the company described as showing significant potential for women with advanced ovarian cancer.A recording and symposium slides are available on IMUNON’s Scientific Presentations page at https://investors.imunon.com/scientific-presentations.

4 months ago

#IMNN IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

www.stocktitan.net/news/IMNN/imunon-public-...

0 0 0 0

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer IMUNON (Nasdaq: IMNN) held an R&D Day on Nov 10, 2025 in New York to present clinical updates for its DNA-mediated immunotherapy IMNN-001 in newly diagnosed advanced ovarian cancer.Presentations reviewed Phase 2 OVATION 2 and an MRD study, highlighted a reported median 13-month overall survival (OS) benefit for IMNN-001 plus standard-of-care chemotherapy, safety and tolerability data, translational findings on tumor microenvironment remodeling, and progress on the pivotal Phase 3 OVATION 3 trial including activation and enrollment updates. A live webcast and materials were made available on the company scientific presentations page.

4 months ago

#IMNN IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

www.stocktitan.net/news/IMNN/imunon-r-d-day...

0 0 0 0

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment IMUNON (Nasdaq: IMNN) will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City with a live webcast option. The event features principal investigators discussing clinical progress for IMNN-001, a DNA-mediated IL-12 immunotherapy in Phase 3 development for advanced ovarian cancer, plus Phase 2 MRD results and Phase 3 statistical design.Speakers include investigators from Washington University, MD Anderson, Berry Consultants, and IMUNON leadership covering OVATION 3/OVATION 2 data, MRD trial immune activation, trial design, enrollment momentum, and near-term clinical milestones. Registration is required to attend in person or virtually.

4 months ago

#IMNN IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

www.stocktitan.net/news/IMNN/imunon-r-d-day...

0 0 0 0

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025 IMUNON (Nasdaq: IMNN) will host a Third Quarter 2025 Financial Results and Business Update conference call on Thursday, November 13, 2025 at 11:00 a.m. ET. The company will discuss results for the quarter ended September 30, 2025 and provide an update on its Phase 3 clinical development program for IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.Dial-in numbers are provided for North America and international participants, a live webcast will be available, and the call will be archived for replay through November 27, 2025 with an audio replay accessible for 90 days.

4 months ago

#IMNN IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

www.stocktitan.net/news/IMNN/imunon-to-hold...

0 0 0 0

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer IMUNON (NASDAQ: IMNN) will host an in-person and virtual R&D Day in New York City on November 10, 2025 at the Harvard Club, starting at 8:00 a.m. ET.The program will provide updates on the pivotal Phase 3 OVATION 3 study and Phase 2 MRD trial for IMNN-001, featuring presentations from ovarian cancer clinicians, Phase 3 investigators, statistical experts, and IMUNON management on safety, translational data, trial design and IMNN-001’s potential role in advanced ovarian cancer. The event includes a live Q&A and networking with speakers.Registration is available for in-person or virtual attendance via RSVP.

4 months ago

#IMNN IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

www.stocktitan.net/news/IMNN/imunon-announc...

0 0 0 0

IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer IMUNON (Nasdaq: IMNN) will host an R&D Day for investors on November 10, 2025 at the Harvard Club in New York City, starting at 8:00 a.m. ET.The program will provide updates on the pivotal Phase 3 OVATION 3 study of IMNN-001 and a Phase 2 MRD trial, featuring presentations from ovarian cancer clinical leaders, Phase 3 investigators, statistical experts and IMUNON management. Presentations will cover safety, translational insights, trial design probability of success, and an OVATION 3 trial update, followed by a live Q&A and networking.

4 months ago

#IMNN IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

www.stocktitan.net/news/IMNN/imunon-hosts-r...

0 0 0 0

5 months ago

🚨 FeetrAI Alert: #IMNN is trading at $5.20 with a cautious outlook! RSI < 50 hints bearish vibes, but MACD shows potential stabilization. Hovering near 20-day SMA support, yet below 30-day SMA. Consider shorting with targets at $5.10 & $5.00. Stop loss: $5.30. Stay sharp! 📉

0 0 0 0

5 months ago

🚨 FeetrAI Alert: #IMNN is trading at $5.13 with a bearish vibe, but watch out for a potential bounce! 📉 RSI hints oversold, while MACD shows a bullish twist. Short at $5.13, target $5.00/$4.90, stop at $5.20. Low volume = unpredictable moves. Stay sharp! 📊 #Stocks #Trading

0 0 0 0

5 months ago

🚀 Exciting times for #IMNN! Trading at $5.11, it's oversold with a positive MACD hinting at a bullish reversal. Consider a LONG position with targets at $5.20 & $5.30. Stop loss at $5.00. Keep an eye on news for potential moves! 📈 #StockMarket #FeetrAI

0 0 0 0

5 months ago

🚀 Exciting times for #IMNN! Promising clinical trial results and a potential big pharma partnership could spark a bullish move. With RSI hinting oversold and MACD showing upward momentum, consider a long position at $5.10. Targets: $5.30 & $5.40. 📈 #FeetrAI

0 0 0 0

5 months ago

#IMNN: OVATION 2 Translational Data Shows IMNN-001 Alters Tumor Microenvironment… buff.ly/jwPl7jD

0 0 0 0

13-Month Survival Extension: IMUNON's Novel Immunotherapy Shows Promise in Advanced Ovarian Cancer Study IMUNON's IMNN-001 demonstrates positive TME shift in 50-80% of patients, with increased anti-tumor cells in Phase 2 OVATION 2 study. Phase 3 trial now underway at 4 sites.

5 months ago

#IMNN IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift

www.stocktitan.net/news/IMNN/imunon-present...

0 0 0 0

7 months ago

#IMNN: First Patient Dosed in Phase 3 OVATION 3 Trial… buff.ly/n5iDlh1

0 0 0 0

IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call IMUNON (NASDAQ: IMNN) provided key updates from its Q2 2025 conference call, highlighting significant progress in its Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer. The company has successfully enrolled and treated its first patient, achieving a rapid launch in just 15 weeks compared to the industry average of 28 weeks.The company announced a 15% stock dividend for shareholders of record as of August 7, 2025. IMUNON has strengthened its financial position by raising over $3 million through warrant exercises and ATM sales. The company expects to meet Nasdaq's compliance requirements, including the Bid Price requirement, by August 8, 2025.The Phase 3 trial features a flexible enrollment strategy starting with 250 HRD-positive patients, reducing costs by approximately 40%, with potential expansion to 500 patients. The company maintains efficient in-house manufacturing for IMNN-001, significantly reducing costs compared to outsourcing.

7 months ago

#IMNN IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call

www.stocktitan.net/news/IMNN/imunon-recaps-...

0 0 0 0

IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update IMUNON (NASDAQ: IMNN) reported Q2 2025 financial results and significant progress in its clinical programs. The company announced a 15% stock dividend and dosed the first patient in its Phase 3 OVATION 3 Study of IMNN-001 for advanced ovarian cancer.Q2 2025 financial highlights include a net loss of $2.7 million ($2.15 per share), improved from $4.8 million loss in Q2 2024. Operating expenses decreased 45% to $2.8 million. Cash position stands at $4.7 million, with additional $3.1 million raised in July 2025.Key developments include positive Phase 2 OVATION 2 Study data showing 13-month median OS improvement, successful completion of a $9.75 million private placement, and a Nasdaq listing compliance extension. The company implemented a 15-for-1 reverse stock split effective July 25, 2025.

7 months ago

#IMNN IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IMNN/imunon-reports...

0 0 0 0

IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer IMUNON (NASDAQ: IMNN) has announced a significant milestone in its clinical development program with the first patient dosed in the pivotal Phase 3 OVATION 3 Study of IMNN-001 for newly diagnosed advanced ovarian cancer. The study evaluates IMNN-001 in combination with standard chemotherapy versus standard care alone.The trial will assess IMNN-001 (100 mg/m2) administered intraperitoneally weekly alongside neoadjuvant and adjuvant chemotherapy. The randomized 1:1 study focuses on women with stage 3C or 4 advanced ovarian cancer, with overall survival as the primary endpoint. The development follows successful Phase 2 OVATION 2 Study results presented at ASCO 2025, which demonstrated meaningful improvements in survival outcomes and favorable safety profiles.

7 months ago

#IMNN IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

www.stocktitan.net/news/IMNN/imunon-announc...

0 0 0 0

IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025 IMUNON (NASDAQ: IMNN), a clinical-stage biotechnology company, has scheduled its second quarter 2025 financial results conference call for August 5, 2025, at 11:00 a.m. ET. The company will discuss Q2 2025 financial performance and provide updates on IMNN-001, their DNA-based interleukin-12 immunotherapy currently in Phase 3 clinical trials for advanced ovarian cancer.Investors can access the call via toll-free numbers or join through a live webcast. A replay will be available until August 19, 2025, through multiple channels including toll-free numbers and a 90-day audio replay on the company's website.

7 months ago

#IMNN IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025

www.stocktitan.net/news/IMNN/imunon-to-hold...

0 0 0 0

IMUNON Announces Reverse Stock Split IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy, has announced a 1-for-15 reverse stock split effective July 25, 2025. The company's outstanding shares will be reduced from 31.8 million to approximately 2.1 million.The reverse split aims to ensure IMUNON meets Nasdaq Capital Market's minimum bid price requirement for continued listing. The stock will continue trading under the symbol "IMNN" but with a new CUSIP number (15117N701). Stockholders approved the split at the July 11 Annual Meeting, authorizing a ratio range of 1-for-5 to 1-for-18.

7 months ago

#IMNN IMUNON Announces Reverse Stock Split

www.stocktitan.net/news/IMNN/imunon-announc...

0 0 0 0

IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, has received an extension from the Nasdaq Hearing Panel to maintain its stock market listing.The Panel has granted IMUNON's request for an exception after reviewing the company's compliance strategies. The company has already achieved compliance with the Equity Rule through recent fundraising activities and must now focus on meeting the minimum shareholder equity requirement and minimum bid price requirement within the approved timeframe.CEO Stacy Lindborg expressed confidence in executing the compliance plan to maintain Nasdaq listing and deliver long-term shareholder value.

8 months ago

#IMNN IMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan

www.stocktitan.net/news/IMNN/imunon-granted...

0 0 0 0

IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period IMUNON (NASDAQ: IMNN), a clinical-stage biotechnology company, has submitted a compliance plan to Nasdaq to address listing requirements concerns. The company is working to meet minimum bid price and stockholders' equity requirements for continued listing on The Nasdaq Capital Market.The company has requested a hearing before The Nasdaq Hearings Panel and expects to receive an additional 180-day compliance period. Trading of IMNN stock will continue during the hearing process. As of May 31, 2025, IMUNON's stockholders' equity exceeds $3.0 million, meeting Nasdaq's listing threshold.IMUNON is currently advancing its lead program, IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer treatment, which is in Phase 3 development. The company has initiated the Phase 3 (OVATION 3) trial in the U.S. and Canada following successful Phase 2 (OVATION 2) trial results.

8 months ago

#IMNN IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period

www.stocktitan.net/news/IMNN/imunon-submits...

0 0 0 0

8 months ago

#IMNN: Translational Data from OVATION 2 Presented… buff.ly/5BTA93f

0 0 0 0

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 IMUNON presented positive Phase 2 translational data for IMNN-001, its DNA-mediated immunotherapy for advanced ovarian cancer, at ESMO Gynaecological Cancers Congress 2025. The OVATION 2 Study involving 112 participants showed that IMNN-001 (100 mg/m2) administered with standard chemotherapy induced significant increases in key anti-cancer immune cytokines: IL-12 (27-fold), IFN-γ (62-fold), and TNF-α (36-fold) in the peritoneal cavity. These results complement previously reported overall survival data at ASCO 2025, where IMNN-001 demonstrated meaningful improvements in overall survival, progression-free survival, and surgical response with a favorable safety profile. The company has initiated its pivotal Phase 3 OVATION 3 Study with two trial sites launched in May 2025.

8 months ago

#IMNN IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

www.stocktitan.net/news/IMNN/imunon-present...

0 0 0 0

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ IMUNON announced that its PlaCCine DNA vaccine technology abstract was selected for oral presentation at the 10th International Conference on Vaccines Research & Development. The Phase 1 trial results of IMNN-101, targeting COVID-19's Omicron XBB1.5 variant, showed promising outcomes with a single dose. Key findings include 6-month durability data demonstrating up to 3-fold median increase in neutralizing antibody titers, with stronger responses in higher dose cohorts (2.0mg and 1.0mg). The vaccine proved safe with no serious adverse effects. PlaCCine technology offers advantages over mRNA vaccines, including better durability, temperature stability, and easier manufacturing. IMUNON is actively seeking strategic partners to advance this technology.

8 months ago

#IMNN IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

www.stocktitan.net/news/IMNN/imunon-announc...

0 0 0 0

Breakthrough at ASCO: IMUNON's Ovarian Cancer Drug Extends Life by 13 Months in Phase 2 Trial New Phase 2 data reveals doubled response rates and 13-month survival benefit in advanced ovarian cancer. Key findings from ASCO presentation show unprecedented results. Learn more.

9 months ago

#IMNN IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

www.stocktitan.net/news/IMNN/imunon-announc...

0 0 0 0

9 months ago

#IMNN: Momentum Continues with Presentations at ASCO and ESMO Gynaecological Cancers… buff.ly/x9VDUH1

0 0 0 0